Galapagos NV (BSP:G1LP34) Total Operating Expense : R$3,430 Mil (TTM As of Mar. 2025)

View and export this data going back to 2020. Start your Free Trial

What is Galapagos NV Total Operating Expense?

Galapagos NV's Total Operating Expense for the three months ended in Mar. 2025 was R$1,369 Mil. Galapagos NV's Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2025 was R$3,430 Mil.

Galapagos NV Total Operating Expense Historical Data

The historical data trend for Galapagos NV's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Galapagos NV Total Operating Expense Chart

Galapagos NV Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Operating Expense

Get a 7-Day Free Trial

4,110.03

4,183.87

2,068.74

1,752.53

2,741.45

Galapagos NV Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Total Operating Expense	Get a 7-Day Free Trial															503.47	576.86	701.51	782.44	1,369.22

Galapagos NV Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.

Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was R$3,430 Mil.

Galapagos NV Total Operating Expense Related Terms

Thank you for viewing the detailed overview of Galapagos NV's Total Operating Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Galapagos NV Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Galapagos NV (BSP:G1LP34) » Definitions » Total Operating Expense

Comparable Companies

Traded in Other Exchanges

GLPGF:USA GLPG:USA GLPG:Netherlands GLPGa:UK 0JXZ:UK GXEA:Germany GXE:Germany GLPG:Austria

Address

Generaal De Wittelaan L11 A3, Mechelen, BEL, 2800

Website

https://www.glpg.com

Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.

Galapagos NV Headlines

No Headlines